How Much Does Vyvanse Cost in Wyoming in 2026?

Wyoming Vyvanse Pricing: List Price vs. What You Actually Pay

The gap between Takeda's $390 list price and the roughly $35 average cash-pay price at Wyoming pharmacies reflects the post-generic pricing shift that reshaped the lisdexamfetamine market. After generic lisdexamfetamine entered the U.S. Market, cash prices dropped significantly at retail counters. Wyoming patients paying out of pocket in 2026 can expect to spend a fraction of the branded sticker price.

Why the List Price Rarely Applies

Takeda's $390 figure represents the wholesale acquisition cost (WAC) for brand-name Vyvanse. Almost no patient pays WAC. Pharmacy benefit managers negotiate rebates, and generic competition has compressed retail margins. The $35 average reflects what uninsured or coupon-using patients typically see at Wyoming chains like Albertsons, Walmart, and independent pharmacies in Cheyenne, Casper, and Laramie.

Price Variation Across Wyoming

Prices can shift by $10 to $20 between pharmacies in the same city. Rural WY pharmacies with limited generic stock may charge more than pharmacies in population centers along the I-25 corridor. Calling ahead or using a price-comparison tool before filling a prescription saves real money, particularly for patients on fixed incomes.

A 2020 analysis published in JAMA Network Open found that out-of-pocket costs for ADHD medications varied by more than 200% across U.S. Retail pharmacies, even within the same ZIP code 1. Wyoming's small pharmacy market amplifies that variability.

Wyoming Medicaid and Vyvanse Coverage

Wyoming Medicaid does not cover Vyvanse or generic lisdexamfetamine on its preferred drug list as of 2026. Patients enrolled in Wyoming Medicaid who need a stimulant for ADHD are typically directed toward covered alternatives such as generic mixed amphetamine salts (Adderall) or generic methylphenidate.

Prior Authorization Workarounds

A prescriber can submit a prior authorization (PA) request arguing medical necessity if a patient has failed or cannot tolerate Medicaid-preferred stimulants. Approval is not guaranteed. The Wyoming Department of Health Pharmacy Benefits program reviews PA requests case by case 2.

Step Therapy Requirements

Wyoming Medicaid uses step therapy for ADHD medications. A patient must typically trial and document inadequate response to at least one preferred amphetamine-class and one preferred methylphenidate-class medication before Medicaid will consider covering a non-preferred agent like lisdexamfetamine. Documentation of adverse effects (e.g., significant appetite suppression, cardiovascular side effects, or rebound symptoms) strengthens the PA request.

According to the American Academy of Pediatrics 2019 ADHD guideline, stimulant medications remain first-line pharmacotherapy for ADHD in patients aged 6 and older, though the guideline does not specify one stimulant formulation over another 3.

Insurance Coverage for Vyvanse in Wyoming

Private insurance plans sold in Wyoming handle Vyvanse coverage differently depending on whether the formulary includes the brand product, the generic, both, or neither. Most commercial plans in the state now cover generic lisdexamfetamine at Tier 2 or Tier 3 copay levels.

Employer-Sponsored Plans

Large employer plans (often self-funded) tend to cover generic lisdexamfetamine with copays ranging from $15 to $50 per month. Brand Vyvanse, if covered at all, usually sits on Tier 3 or a specialty tier with copays of $75 to $150. Some plans require prior authorization for brand when a generic equivalent is available.

ACA Marketplace Plans

Wyoming ACA marketplace plans from insurers like Blue Cross Blue Shield of Wyoming and Friday Health Plans include ADHD medications in their formularies, but tier placement varies by metal level. Bronze and Silver plans frequently place lisdexamfetamine at higher cost-sharing tiers. Patients should check formulary documents during open enrollment rather than assuming coverage.

TRICARE

Active-duty military families and retirees in Wyoming covered by TRICARE can fill generic lisdexamfetamine at military pharmacies (F.E. Warren Air Force Base in Cheyenne) for $0 or at retail pharmacies for the standard TRICARE copay. The Department of Defense formulary includes generic lisdexamfetamine 4.

Compounded Lisdexamfetamine in Wyoming

Compounded lisdexamfetamine is available through licensed 503A compounding pharmacies in Wyoming. This is legal under federal law (the Drug Quality and Security Act of 2013) when a prescriber writes a patient-specific prescription and the pharmacy holds a valid state compounding license.

What 503A Means for Wyoming Patients

A 503A pharmacy compounds medications for individual patients based on a specific prescription. Wyoming's Board of Pharmacy regulates these facilities. The compounded product is not FDA-approved, and quality can vary between pharmacies. Patients should confirm that their compounding pharmacy is licensed and inspected.

Cost of Compounded Lisdexamfetamine

Compounded lisdexamfetamine pricing in Wyoming starts near $0 through some telehealth-affiliated compounding arrangements, though typical out-of-pocket costs at independent compounding pharmacies range from $30 to $90 per month depending on dose and capsule count. Insurance plans rarely cover compounded medications.

A note on clinical equivalence: compounded lisdexamfetamine may not replicate the exact pharmacokinetic profile of brand Vyvanse. Wigal et al. (2017) demonstrated that Vyvanse's prodrug mechanism produces a predictable, smooth d-amphetamine release curve over 10 to 14 hours 5. Compounded versions should aim to match this profile, but bioequivalence testing is not required for 503A products.

Takeda Savings Card and Manufacturer Discounts

Takeda offers a Vyvanse Savings Card for commercially insured patients. Eligible patients may pay as low as $30 per month for brand Vyvanse. The card cannot be used with Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility Criteria

To qualify, a patient must have commercial insurance that covers Vyvanse (even at a high copay tier) and must not be enrolled in any state or federal healthcare program. The savings card offsets the difference between the patient's copay and the $30 target. Annual caps apply. Takeda updates the program terms periodically, so patients should verify current terms on the Takeda patient support website.

What If You're Uninsured?

Takeda's Help at Hand patient assistance program provides brand Vyvanse at no cost to uninsured patients who meet income thresholds (generally at or below 250% of the federal poverty level). For a single-person household in Wyoming, that threshold was approximately $38,295 in 2025 6. Application requires proof of income and a valid prescription.

For patients above the income threshold who remain uninsured, the $35 average generic cash price represents the most cost-effective route.

Telehealth Prescribing of Vyvanse in Wyoming

Wyoming permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, under state telemedicine regulations. The DEA's post-pandemic telehealth prescribing flexibility (extended through 2025 and into 2026 under interim rules) allows an initial Schedule II prescription via audio-video evaluation without a prior in-person visit 7.

How It Works in Practice

A Wyoming-licensed prescriber conducts a synchronous video visit, completes an ADHD evaluation (or reviews existing documentation), and sends the electronic prescription to a Wyoming pharmacy. E-prescribing is mandatory for Schedule II substances in Wyoming as of 2023.

Wyoming-Specific Telehealth Rules

Wyoming does not impose additional state-level restrictions beyond federal DEA requirements for telehealth prescribing of controlled substances. The Wyoming Board of Medicine requires that telehealth providers hold a Wyoming medical license or practice under the Interstate Medical Licensure Compact, which Wyoming has adopted. This gives patients in rural areas (Sheridan, Gillette, Rock Springs) access to ADHD-specialized prescribers who may not practice locally.

The Endocrine Society has noted that telehealth expands access to specialty care in states with low provider density, a category that includes Wyoming with its population of approximately 577,000 spread across 97,813 square miles 8.

How to Find the Lowest Vyvanse Price in Wyoming

Step 1: Confirm Generic Availability

Ask your prescriber to write for generic lisdexamfetamine. Not all pharmacies stock it consistently, and some may default to brand unless the prescription specifies "substitution permitted."

Step 2: Compare Pharmacy Prices

Call or check online pricing at three or more pharmacies. Walmart, Costco (no membership required for pharmacy), and Smith's tend to offer competitive generic pricing in Wyoming.

Step 3: Apply a Discount Card

Free prescription discount cards (GoodRx, RxSaver, SingleCare) can reduce generic lisdexamfetamine prices below the pharmacy's standard cash rate. These cards work at most chain pharmacies in Wyoming. Discounts are not insurance and cannot be combined with insurance copays.

Step 4: Explore Compounded Options

If cost remains prohibitive, discuss compounded lisdexamfetamine with your prescriber. Confirm the compounding pharmacy is Wyoming Board of Pharmacy-licensed and request documentation of their quality assurance process.

Step 5: Apply for Patient Assistance

Uninsured patients below income thresholds should apply to Takeda's Help at Hand program. Processing takes 4 to 6 weeks, so plan ahead before running out of medication.

Clinical Context: Why Lisdexamfetamine Costs What It Does

Lisdexamfetamine is a prodrug. The body converts it to d-amphetamine after oral ingestion, producing a smoother onset and longer duration than immediate-release amphetamine formulations. This pharmacokinetic advantage was a key differentiator during Vyvanse's patent-protected years and justified its premium price.

The Generic Transition

Vyvanse's composition-of-matter patent expired, and generic lisdexamfetamine entered the U.S. Market. Generic manufacturers (Teva, Alvogen, and others) submitted Abbreviated New Drug Applications (ANDAs) demonstrating bioequivalence to brand Vyvanse 9. The FDA's Orange Book lists these approved generics. Their entry collapsed cash-pay prices from the $300+ range to under $50 at most pharmacies.

Efficacy Data

In the key trial by Wigal et al. (2017), lisdexamfetamine dimesylate significantly improved ADHD Rating Scale (ADHD-RS-IV) scores compared to placebo across pediatric and adult populations. Effect sizes were large (Cohen's d > 0.8), consistent with the broader stimulant literature 5.

For binge eating disorder, the FDA approved Vyvanse based on two randomized controlled trials (Study 001 and Study 002, N=724 combined) showing that lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by approximately 3.87 days compared to 2.51 days for placebo at 12 weeks 10.

"Lisdexamfetamine's prodrug design reduces the abuse liability compared to immediate-release amphetamine formulations," according to the FDA's clinical pharmacology review in the Vyvanse label 9.

Wyoming-Specific Considerations for ADHD Patients

Wyoming's provider shortage affects ADHD care. The state has fewer than 20 practicing psychiatrists, and most are concentrated in Cheyenne and Casper. Primary care providers write the majority of ADHD prescriptions statewide. This is consistent with national data from the CDC showing that approximately 55% of children with ADHD receive their prescriptions from primary care rather than specialists 11.

Refill Logistics in Rural Wyoming

Schedule II prescriptions cannot be called in. Wyoming's e-prescribing mandate helps, but patients in remote areas (Big Horn Basin, the Wind River region) may face 30- to 60-mile drives to the nearest pharmacy that stocks generic lisdexamfetamine. Mail-order pharmacy is an option for maintenance prescriptions, though some insurers restrict mail-order for Schedule II medications.

Altitude and Stimulant Pharmacology

Wyoming's mean elevation exceeds 6,700 feet. No published evidence suggests that altitude clinically alters lisdexamfetamine pharmacokinetics. Cardiovascular monitoring (heart rate, blood pressure) remains standard at any elevation, per the FDA label's boxed warning about serious cardiovascular events in patients with pre-existing structural cardiac abnormalities 9.